多发性骨髓瘤新冠患者抗体应答优于完全接种BNT162b2疫苗患者
本研究比较了未接种疫苗的多发性骨髓瘤(MM)合并COVID-19患者与接种两剂BNT162b2疫苗的MM患者的中和抗体(NAb)水平。提示接受治疗的接种MM患者应考虑加强针。
要点
- MM合并COVID-19患者中和抗体滴度高于接种BNT162b2疫苗的MM患者。
- 未治疗亚组中,COVID-19阳性与疫苗接种患者NAb无显著差异。
- 接受治疗的MM患者接种疫苗后应考虑加强剂量。
核心结论
- MM合并COVID-19患者比接种两剂BNT162b2疫苗的MM患者产生更高的中和抗体应答。
- 未接受治疗的MM患者中,感染与接种疫苗后的中和抗体水平无差异。
研究设计与样本
- 研究纳入35例未接种疫苗的MM合并COVID-19患者和35例匹配的接种两剂BNT162b2疫苗的MM患者。
- 血清采集时间为确诊后四周或第二剂疫苗接种后四周。
- 采用FDA批准的酶联免疫吸附法检测中和抗体。
临床怎么用
- 接受治疗且无COVID-19病史的MM患者接种疫苗后应考虑加强针。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with multiple myeloma (MM) have a suboptimal antibody response following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and lower seroconversion rates following coronavirus disease 2019 (COVID-19) compared with healthy individuals. In this context, we evaluated the development of neutralising antibodies (NAbs) against SARS-CoV-2 in non-vaccinated patients with MM and COVID-19 compared with patients after vaccination with two doses of the BNT162b2 vaccine. Serum was collected either four weeks post confirmed diagnosis or four weeks post a second dose of BNT162b2. NAbs were measured with a Food and Drug Administration-approved enzyme-linked immunosorbent assay methodology. Thirty-five patients with COVID-19 and MM along with 35 matched patients were included. The two groups did not differ in age, sex, body mass index, prior lines of therapy, disease status, lymphocyte count, immunoglobulin levels and comorbidities. Patients with MM and COVID-19 showed a superior humoral response compared with vaccinated patients with MM. The median (interquartile range) NAb titre was 87·6% (71·6-94%) and 58·7% (21·4-91·8%) for COVID-19-positive and vaccinated patients, respectively (P = 0·01).Importantly, there was no difference in NAb production between COVID-19-positive and vaccinated patients who did not receive any treatment (median NAb 85·1% vs 91·7%, P = 0·14). In conclusion, our data indicate that vaccinated patients with MM on treatment without prior COVID-19 should be considered for booster vaccine doses.
引用
- Gavriatopoulou M, Terpos E, Malandrakis P, et al. Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. Br J Haematol. 2021. PMID: 34528249. doi:10.1111/bjh.17841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。